Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: A systematic review

Arthritis Care and Research

Volumn 65, Issue 11, 2013, Pages 1775-1785

  Pego Reigosa, José M ^a   Cobo Ibáñez, Tatiana ^b   Calvo Alén, Jaime ^c   Loza Santamaría, Estíbaliz ^d   Rahman, Anisur ^e   Muñoz Fernández, Santiago ^b   Rúa Figueroa, Íñigo ^f  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c Sierrallana Hospi Tal ^*  (Spain)

^d Institute for Health   (Spain)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^f HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ENALAPRIL; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; TACROLIMUS;

COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EMBASE; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; INTERVENTION STUDY; MEDLINE; META ANALYSIS; OPEN STUDY; OUTCOME ASSESSMENT; OUTCOME VARIABLE; OVARY INSUFFICIENCY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SLEDAI; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UTERINE CERVIX CARCINOMA IN SITU;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

EID: 84887032483     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22035     Document Type: Review

References (86)

1. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9.
2. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-5.
3. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996; 125: 549-57.
4. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31.
5. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al, for the MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69: 2083-9.
6. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al, for the Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-62.
7. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-28.
8. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al, for the Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-12.
9. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al. Sequential therapies for proliferative lupus. N Engl J Med 2004; 350: 971-80.
10. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al, for the ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-95.
11. Wallace DJ, Kalunian KC, Petri MA, Strand V, Kilgallen B, Kelley L, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Ann Rheum Dis 2010; 69 Suppl 3: 605.
12. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab, a humanized antiCD20 antibody, in patients with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III BELONG study [abstract]. Arthritis Rheum 2010; 62 Suppl: S606.
13. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial. Arthritis Rheum 2010; 62: 222-33.
14. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment With Rituximab Study. Arthritis Rheum 2012; 64: 1215-26.
15. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 3077-87.
16. Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study [abstract]. Arthritis Rheum 2011; 63 Suppl: S962.
17. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30.
18. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
19. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, et al. Oxford Centre for Evidence-based Medicine levels of evidence. 2011. URL: http://www.cebm.net/index.aspx?o=1025.
20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
21. Stojanovich L, Stojanovich R, Kostich V, Dzjolich E,. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 2003; 12: 3-7.
22. Gonzalez-Lopez L, Cardona-Munoz EG, Celis A, Garcia-de la Torre I, Orozco-Barocio G, Salazar-Paramo M, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 2004; 13: 105-12.
23. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 620-5.
24. Petri M, Brodsky RA, Jones RJ, Gladstone D, Fillius M, Magder LS,. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum 2010; 62: 1487-93.
25. Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE,. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-9.
26. De Bandt M, Goycochea MV, Meyr O, Delahousse M, Palazzo E, M'Bappe P, et al. Treatment of acute systemic lupus erythematosus with intravenous infusions of cyclophosphamide: value and limitations. Ann Med Interne (Paris) 1994; 145: 75-87. In French.
27. Gonzalez LA, McGwin G Jr, Duran S, Pons-Estel GJ, Apte M, Vila LM, et al. Predictors of premature gonadal failure in patients with systemic lupus erythematosus: results from LUMINA, a multiethnic US cohort (LUMINA LVIII). Ann Rheum Dis 2008; 67: 1170-3.
28. Gonzalez LA, Pons-Estel GJ, Zhang JS, McGwin G Jr, Roseman J, Reveille JD, et al. Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII). Lupus 2009; 18: 184-6.
29. Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide: a study in 84 patients. J Rheumatol 2002; 29: 2571-6.
30. Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM,. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 2002; 29: 2129-35.
31. Kang KY, Kim HO, Yoon HS, Lee J, Lee WC, Ko HJ, et al. Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol 2010; 29: 381-8.
32. Katsifis GE, Tzioufas AG, Vlachoyiannopoulos PG, Voulgarelis M, Moutsopoulos HM, Ioannidis JP,. Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2002; 41: 780-6.
33. Manger K, Wildt L, Kalden JR, Manger B,. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev 2006; 5: 269-72.
34. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR,. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997; 56: 481-7.
35. Martinez-Martinez MU, Abud-Mendoza C,. Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus. Lupus 2011; 20: 568-74.
36. Massardo L, Martinez ME, Baro M, Figueroa F, Rivero S, Jacobelli S,. Infections in systemic lupus erythematosus. Rev Med Chil 1991; 119: 1115-22.
37. Medeiros MM, Silveira VA, Menezes AP, Carvalho RC,. Risk factors for ovarian failure in patients with systemic lupus erythematosus. Braz J Med Biol Res 2001; 34: 1561-8.
38. Mok CC, Ho CT, Wong RW, Lau CS,. Damage accrual in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1513-9.
39. Mok CC, Wong RW, Lau CS,. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1274-80.
40. Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG,. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98: 32-41.
41. Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004; 31: 1763-7.
42. Petri M, Jones RJ, Brodsky RA,. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 166-73.
43. Ramos PC, Mendez MJ, Ames PR, Khamashta MA, Hughes GR,. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14: 295-9.
44. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M,. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182-9.
45. Vinet E, Clarke AE, Gordon C, Urowitz MB, Hanly JG, Pineau CA, et al. Decreased live births in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63: 1068-72.
46. Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, Moutsopoulos HM,. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 1768-75.
47. Wang CL, Wang F, Bosco JJ,. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995; 4: 11-4.
48. Williams FM, Chinn S, Hughes GR, Leach RM,. Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome. Ann Rheum Dis 2002; 61: 414-21.
49. Zamora MR, Warner ML, Tuder R, Schwarz MI,. Diffuse alveolar hemorrhage and systemic lupus erythematosus: clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997; 76: 192-202.
50. Hahn BH, Kantor OS, Osterland CK,. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients. Ann Intern Med 1975; 83: 597-605.
51. Oelzner P, Abendroth K, Hein G, Stein G,. Predictors of flares and long-term outcome of systemic lupus erythematosus during combined treatment with azathioprine and low-dose prednisolone. Rheumatol Int 1996; 16: 133-9.
52. Carneiro JR, Sato EI,. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999; 26: 1275-9.
53. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M, for the Canadian Network for Improved Outcomes in Systemic Lupus. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008; 59: 1796-804.
54. Arfi S, Numeric P, Grollier L, Panelatti G, Jean-Baptiste G,. Treatment of corticodependent systemic lupus erythematosus with low-dose methotrexate. Rev Med Interne 1995; 16: 885-90. In French.
55. Guil Garcia M, Garcia Portales R, Fernandez Nebro A, Belmonte Lopez MA, Camps Garcia MT, de Ramon Garrido E,. Effectiveness of the treatment of systemic lupus erythematosus with methotrexate. Med Clin (Barc) 1993; 101: 361-4.
56. Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M,. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997; 56: 382-5.
57. Wilke WS, Krall PL, Scheetz RJ, Babiak T, Danao T, Mazanec DJ, et al. Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases. Clin Exp Rheumatol 1991; 9: 581-7.
58. Wilson K, Abeles M,. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21: 1674-7.
59. Wise CM, Vuyyuru S, Roberts WN,. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease: a review of 36 patients. J Rheumatol 1996; 23: 1005-10.
60. Tam LS, Li EK, Wong CK, Lam CW, Szeto CC,. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004; 13: 601-4.
61. Remer CF, Weisman MH, Wallace DJ,. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001; 10: 480-3.
62. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA, for the ALMS Group. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010; 62: 211-21.
63. Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG,. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003; 62: 534-9.
64. Bolad W, Magder L, Petri M,. Immunosuppressive drugs in SLE differ in their hematologic side-effects [abstract]. Arthritis Rheum 2009; 60 Suppl: S104.
65. Karim MY, Alba P, Cuadrado MJ, Abbs IC, D'Cruz DP, Khamashta MA, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002; 41: 876-82.
66. Nannini C, Crowson CS, Matteson EL, Moder KG,. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study. Lupus 2009; 18: 394-9.
67. Pisoni CN, Sanchez FJ, Karim Y, Cuadrado MJ, D'Cruz DP, Abbs IC, et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047-52.
68. Posalski JD, Ishimori M, Wallace DJ, Weisman MH,. Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. Lupus 2009; 18: 516-21.
69. Riskalla MM, Somers EC, Fatica RA, McCune WJ,. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1508-12.
70. Dammacco F, Della Casa Alberighi O, Ferraccioli G, Racanelli V, Casatta L, Bartoli E,. Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int J Clin Lab Res 2000; 30: 67-73.
71. Griffiths B, Emery P, Ryan V, Isenberg D, Akil M, Thompson R, et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford) 2010; 49: 723-32.
72. Manger K, Kalden JR, Manger B,. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996; 35: 669-75.
73. Caccavo D, Lagana B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997; 40: 27-35.
74. Conti F, Priori R, Alessandri C, Spinelli FR, Medda E, Valesini G,. Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A. Lupus 2000; 9: 676-80.
75. Morton SJ, Powell RJ,. An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use. Ann Rheum Dis 2000; 59: 487-9.
76. Ogawa H, Kameda H, Amano K, Takeuchi T,. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 2010; 19: 162-9.
77. Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994; 37: 551-8.
78. Suzuki K, Kameda H, Amano K, Nagasawa H, Takei H, Nishi E, et al. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatol Int 2011; 31: 757-63.
79. Kusunoki Y, Tanaka N, Kaneko K, Yamamoto T, Endo H, Kawai S,. Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study. Mod Rheumatol 2009; 19: 616-21.
80. Andrade RM, Alarcon GS, Gonzalez LA, Fernandez M, Apte M, Vila LM, et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis 2008; 67: 829-34.
81. Ho KT, Ahn CW, Alarcon GS, Baethge BA, Tan FK, Roseman J, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005; 44: 1303-7.
82. Kaiser R, Cleveland CM, Criswell LA,. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009; 68: 238-41.
83. Noel V, Lortholary O, Casassus P, Cohen P, Genereau T, Andre MH, et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 2001; 60: 1141-4.
84. Ramsey-Goldman R, Mientus JM, Kutzer JE, Mulvihill JJ, Medsger TA Jr,. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol 1993; 20: 1152-7.
85. Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Szegedi G, et al. Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center. Ann N Y Acad Sci 2007; 1108: 76-82.
86. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y,. Systemic lupus erythematosus one disease or many? Autoimmun Rev 2012; 11: 593-5.